Compare ARVN & NVRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | NVRI |
|---|---|---|
| Founded | 2015 | 1853 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 582.1M |
| IPO Year | 2018 | 2026 |
| Metric | ARVN | NVRI |
|---|---|---|
| Price | $8.27 | $20.65 |
| Analyst Decision | Buy | |
| Analyst Count | 19 | 0 |
| Target Price | ★ $15.05 | N/A |
| AVG Volume (30 Days) | ★ 711.6K | 255.4K |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | $3.87 |
| Revenue Next Year | N/A | $3.70 |
| P/E Ratio | $4.89 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.97 | $11.15 |
| 52 Week High | $14.22 | $24.20 |
| Indicator | ARVN | NVRI |
|---|---|---|
| Relative Strength Index (RSI) | 38.71 | 39.60 |
| Support Level | $7.90 | $20.27 |
| Resistance Level | $8.40 | $23.68 |
| Average True Range (ATR) | 0.32 | 0.77 |
| MACD | -0.13 | -0.24 |
| Stochastic Oscillator | 11.88 | 6.11 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Enviri Corp provides environmental and operational solutions to the metal and rail industries. It is based in Philadelphia, Pennsylvania, and operates in more than 30 countries. The company leverages industrial expertise to help customers improve operational performance, recover value from byproducts, enhance sustainability, and maintain critical infrastructure. Its divisions are Harsco Environmental and Harsco Rail, which combine deep operational capabilities with technologies and world-wide scale to deliver long-term value for customers, communities, and shareholders.